Teva Branded Pharmaceutical Products R&D
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Teva Branded Pharmaceutical Products R&D sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).
Teva Branded Pharmaceutical Products R&D: 167 sponsored US clinical trials, 6 recruiting.
Teva Branded Pharmaceutical Products R&D sponsors 167 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 131 completed. 89 of these trials are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 13 trials.
Top-decile sponsor footprint
Teva Branded Pharmaceutical Products R&D ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
131 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
167 total, page 4 of 4
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
NCT00375219
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
NCT00336557
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
NCT00308685
Non-invasive Measures of Distal Lung Disease in Asthmatics
NCT00250341
Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics
NCT00112411
Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children
NCT00094016
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
NCT00104273
Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids
NCT00109668
Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma
NCT00085774
Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
NCT00071552
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
NCT00202982
Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique
NCT00054964
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
NCT00203164
Multicenter Trial For Patients With Acute Crohn's Disease
NCT00035503
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
NCT00203177
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
NCT00203034
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 37 |
| Phase 3 | 79 |
| Phase 4 | 10 |
Therapeutic Areas
What is open in the Teva Branded Pharmaceutical Products R&D pipeline
6 recruiting of 167 indexed (4% open); 131 completed (78%).
Phase mix: 89 late (III/IV) vs 74 early (I/II) (balanced across stages).
Top condition: Asthma (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Teva Branded Pharmaceutical Products R&D: open-pipeline peers nationwide
Peers matched on 167 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Teva Branded Pharmaceutical Products R&D sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 167 trials (± recruiting share)
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Bayer · 4% recruiting · 591 trials
Related
What to do with this Teva Branded Pharmaceutical Products R&D page
167 registered trials is a research-attention snapshot, not an endorsement of Teva Branded Pharmaceutical Products R&D or any single study.
- 6 of Teva Branded Pharmaceutical Products R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Asthma is the condition Teva Branded Pharmaceutical Products R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Teva Branded Pharmaceutical Products R&D pipeline card: 167 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.